Medical Affairs
Publications & Presentations
Information provided in these publications, posters and presentations is intended for scientific review by medical professionals. This information is not considered medical advice and is not intended to promote the sale of any drug product.
For more information on GIAPREZA, including important safety information, please visit www.GIAPREZA.com.
For more information on XERAVA, including important safety information, please visit www.XERAVA.com.
For more information on XACDURO, including important safety information, please visit www.XACDURO.com.
Filter by Product
Marketed
Investigational
No results
Zoliflodacin
Oral zoliflodacin for treatment of uncomplicated gonorrhoea: Subgroup analyses of a global Phase 3 randomised controlled clinical trialAuthor Name
A Luckey, H Broadhurst, E Bettiol, S Srinivasan, EW Hook III
Date Published
September 2024
Zoliflodacin
Recommendations for the optimal introduction of novel antibiotics to treat uncomplicated gonorrhoea in the face of increasing antimicrobial resistance: a case study with zoliflodacinAuthor Name
F Pascual, C Au, CD Chikwari, P Daram, C Deal, A Espinosa Miranda, YH Grad, EW Hook III, R Kittiyaowamarn, A Luckey, N Low, V Maseko, RPH Peters, T Roberts , M Unemo, S Srinivasan and the Chicago Workshop expert group
Date Published
September 2024
Zoliflodacin
Descriptive analysis of sexually transmitted infections risk factors among participants included in the global zoliflodacin Phase 3 clinical trialAuthor Name
Luckey A, Broadhurst H, Bettiol E, Srinivasan S for the zoliflodacin Phase 3 study group
Date Published
September 2024
Zoliflodacin
Oral zoliflodacin for treatment of uncomplicated gonorrhea: Subgroup analyses by sex at birth, race and region of a global Phase 3 randomized controlled clinical trialAuthor Name
S Srinivasan, A Luckey, H Broadhurst, JP Mueller, D Lewis, E Bettiol, and EW Hook III
Date Published
September 2024
Zoliflodacin
In Vitro Activity of Zoliflodacin against Contemporary Neisseria gonorrhoeae Isolates from the United StatesAuthor Name
McLeod SM, Moussa SH, Au C, Hackel M, Kaplan N, Mueller JP and Srinivasan S
Date Published
September 2024
Zoliflodacin
Interactions between Zoliflodacin and Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enzymological Basis for Cellular Targeting.Author Name
Collins JA, Basarab GS, Chibale K, Osheroff N.
Date Published
July 2024
XACDURO®
IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative InfectionsAuthor Name
Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, & Bonomo RA
Date Published
July 2024
XERAVA®
The Surgical Infection Society Guidelines on the Management of Intra-Abdominal Infection: 2024 UpdateAuthor Name
Huston JM, Barie PS, Dellinger EP, Forrester JD, Duane TM, Tessier JM, Sawyer RG, Cainzos MA, Rasa K, Chipman JG, Kao LS, Pieracci FM, Colling KP, Heffernan DS, Lester J
Date Published
July 2024
XACDURO®
In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complexAuthor Name
McLeod SM, Carter NM, Bradford PA, Miller AA
Date Published
May 2024
XACDURO®
In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complexAuthor Name
McLeod SM, Carter NM, Bradford PA, Miller AA.
Date Published
May 2024
XACDURO®
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK)Author Name
Miller AA, Moussa SH, McLeod SM.
Date Published
May 2024
Zoliflodacin
Antimicrobial susceptibility of baseline Neisseria gonorrhoeae isolates from participants recruited in the global zoliflodacin Phase 3 randomised controlled trialAuthor Name
Luckey A, Elango V, Bettiol E, Piddock L, Unemo M, Bradford P, McLeod S, Mueller J, Srinivasan S
Date Published
April 2024
Zoliflodacin
Safety profile of oral zoliflodacin for uncomplicated gonorrhoea in a Phase 3 trialAuthor Name
Kornmann G, Johnstone H, Wansom T, Srinivasan S, Lewis D, Luckey A
Date Published
April 2024
Zoliflodacin
Pharmacokinetics of zoliflodacin in healthy participants in the presence of itraconazole suggest no clinically meaningful CYP3A4-mediated drug-drug interactionsAuthor Name
Luckey A, Rayad N, Heep M, Delhomme S, Kornmann G, Larson KB, Mueller JP, O’Donnell JP, O’Brien S, Fuhr R, Gillon JY
Date Published
April 2024
XACDURO®
Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumanniiAuthor Name
Franzone JP, Mackow NA, van Duin D
Date Published
April 2024
GIAPREZA®
Dysfunction of the renin-angiotensin-aldosterone system in human septic shockAuthor Name
Schaich CL, Leisman DE, Goldberg MB, Filbin MR, Khanna AK, Chappell MC
Date Published
March 2024
Zoliflodacin
The formulation of zoliflodacin for commercial use is bioequivalent to the Phase 3 pivotal trial formulation in fed and fasted statesAuthor Name
Noha Rayad*, Alison Luckey*, Markus Heep, Sophie Delhomme, Gabrielle Kornmann, Kajal B Larson, John P Mueller, John P O’Donnell, Seamus O’Brien, Rainard Fuhr, Jean-Yves Gillon
Date Published
March 2024
GIAPREZA®
Renin Levels and Angiotensin II Responsiveness in Vasopressor-Dependent HypotensionAuthor Name
See EJ, Chaba A, Spano S, Maeda A, Clapham C, Burrell LM, Liu J, Khasin M, Liskaser G, Eastwood G, Bellomo R
Date Published
March 2024
GIAPREZA®
Plasma renin as a novel prognostic biomarker of sepsis-associated acute respiratory distress syndromeAuthor Name
Chakradhar A, Baron RM, Vera MP, Devarajan P, Chawla L, Hou PC
Date Published
March 2024
XACDURO®
Comparison of clinical outcomes for patients with monomicrobial vs polymicrobial Acinetobacter baumannii-calcoaceticus complex infections treated with sulbactam-durlobactam or colistin: A subset analysis from a phase 3 clinical trialAuthor Name
McLeod SM, Miller AA, Rana K, Altarac D, Moussa SH, Shapiro AB
Date Published
March 2024
XACDURO®
In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitalsAuthor Name
Iovleva A, McElheny CL, Fowler EL, Cober E, Herc ES, Arias CA, Hill C, Baum K, Fowler VG Jr, Chambers HF, Greenwood-Quaintance KE, Patel R, van Duin D, Bonomo RA, Doi Y
Date Published
March 2024
XACDURO®
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumanniiAuthor Name
McLeod SM, O'Donnell JP, Narayanan N, Mills JP, Kaye KS
Date Published
March 2024
GIAPREZA®
Clinical Response to Third-Line Angiotensin-II vs Epinephrine in Septic Shock: A Propensity-Matched Cohort StudyAuthor Name
Blankenship CR, Betthauser KD, Hencken LN, Maamari JA, Goetz J, Giacomino BD, Gibson GA
Date Published
February 2024
GIAPREZA®
A Pilot Study of Renin-Guided Angiotensin-II Infusion to Reduce Kidney Stress After Cardiac SurgeryAuthor Name
Sadjadi M, von Groote T, Weiss R, Strauß C, Wempe C, Albert F, Langenkämper M, Landoni G, Bellomo R, Khanna AK, Coulson T, Meersch M, Zarbock A
Date Published
January 2024
XACDURO®
Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug-resistant Acinetobacter baumannii Infections – A Systematic ReviewAuthor Name
Velmurugan H, Venkatesan S, Meles HN, Thangaraju P, Neelambaram
Date Published
January 2024
GIAPREZA®
Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shockAuthor Name
Leisman DE, Handisides DR, Chawla LS, Albertson TE, Busse LW, Boldt DW, Deane AM, Gong MN, Ham KR, Khanna AK, Ostermann M, McCurdy MT, Thompson BT, Tumlin JS, Adams CD, Hodges TN, Bellomo R
Date Published
December 2023
XACDURO®
Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumanniiAuthor Name
Karruli A, Migliaccio A, Pournaras S, Durante-Mangoni E, Zarrilli R
Date Published
December 2023
GIAPREZA®
Is It Time to Reconsider the Concept of “Salvage Therapy” in Refractory Shock?Author Name
Wieruszewski PM, Sevransky JE, Roberts RJ
Date Published
December 2023
GIAPREZA®
Angiotensin II for the Treatment of Refractory Shock: A Matched AnalysisAuthor Name
Smith LM, Mentz GB, Engoren MC
Date Published
December 2023
GIAPREZA®
Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trialAuthor Name
Bokoch MP, Tran AT, Brinson EL, Marcus SG, Reddy M, Sun E, Roll GR, Pardo M, Fields S, Adelmann D, Kothari RP, Legrand M
Date Published
November 2023
XACDURO®
Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumanniiAuthor Name
Moussa SH, Shapiro AB, McLeod SM, Iyer R, Carter NM, Tsai Y-K, Siu LK, Miller AA.
Date Published
November 2023
GIAPREZA®
Renin as a Prognostic Marker in Intensive Care and Perioperative Settings: A Scoping ReviewAuthor Name
Teixeira JP, Perez Ingles D, Barton JB, Dean JT, Garcia P, Kunkel SJ, Sarangarm P, Weiss NK, Schaich CL, Busse LW, Nielsen ND
Date Published
October 2023
GIAPREZA®
Renin as a Prognostic Marker in Intensive Care and Perioperative Settings: A Scoping ReviewAuthor Name
Kotani Y, Belletti A, Maiucci G, Lodovici M, Fresilli S, Landoni G, Bellomo R, Zarbock A
Date Published
October 2023
XERAVA®
Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Enterobacterales IsolatesAuthor Name
Teo JQ, Chang HY, Tan SH, Tang CY, Ong RT, Ko KKK, Chung SJ, Tan TT, Kwa AL
Date Published
June 2023
XACDURO®
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)Author Name
Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D
Date Published
May 2023
GIAPREZA®
Trajectory of PaO2/FiO2 Ratio in Shock After Angiotensin IIAuthor Name
Wieruszewski PM, Coleman PJ, Levine AR, Davison D, Smischney NJ, Kethireddy S, Guo Y, Hecht J, Mazzeffi MA, Chow JH
Date Published
May 2023
XERAVA®
Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials.Author Name
Chen TY, Hsu CK, Shih SC, Weng TS, Tang HJ, Lai CC
Date Published
May 2023
GIAPREZA®
Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trialAuthor Name
Wieruszewski PM, Bellomo R, Busse LW, Ham KR, Zarbock A, Khanna AK, Deane AM, Ostermann M, Wunderink RG, Boldt DW, Kroll S, Greenfeld CR, Hodges T, Chow JH
Date Published
May 2023
XACDURO®
Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) InfectionsAuthor Name
Watkins RR, Bonomo RA
Date Published
May 2023
GIAPREZA®
A Pilot Study Of Angiotensin II As Primary Vasopressor In Critically Ill Adults With Vasodilatory Hypotension: The Aramis StudyAuthor Name
Emily J See, Caroline Clapham, Jasmine Liu, Monique Khasin
Date Published
May 2023
XERAVA®
Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysisAuthor Name
Kong W, Deng T, Li S, Shu Y, Wu Y
Date Published
April 2023
XERAVA®
Multicenter Clinical Evaluation of ETEST Eravacycline for Susceptibility Testing of Enterobacteriaceae and EnterococciAuthor Name
Blanchard LS, Armstrong TP, Kresken M, Emery CL, Ying YX, Sauvonnet V, Zambardi G
Date Published
March 2023
XERAVA®
In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancerAuthor Name
Rolston K, Gerges B, Nesher L, Shelburne SA, Prince R, Raad I
Date Published
March 2023
XERAVA®
Carbapenem-Resistant Klebsiella pneumoniae: Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment OptionsAuthor Name
Karampatakis T, Tsergouli K, Behzadi P
Date Published
January 2023
XERAVA®
In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing EnterobacteralesAuthor Name
Bonnin RA, Bernabeu S, Emeraud C, Naas T, Girlich D, Jousset AB, Dortet L
Date Published
January 2023
GIAPREZA®
Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory SupportAuthor Name
Wieruszewski PM, Seelhammer TG, Barreto EF, Busse LW, Chow JH, Davison DL, Gaglani B, Khanna AK, Ten Lohuis CC, Mara KC, Wittwer ED
Date Published
December 2022
XERAVA®
In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolatesAuthor Name
Zeng W, Zhang X, Liu Y, Zhang Y, Xu M, Wang S, Sun Y, Zhou T, Chen L
Date Published
November 2022
XERAVA®
Comparative in vitro activities of omadacycline, eravacycline and tigecycline against non-ESBL-producing, ESBL-producing and carbapenem-resistant isolates of K. pneumoniaeAuthor Name
Mirza HC, Güçlü AÜ, İnce Ceviz G, Başustaoğlu A
Date Published
October 2022
Zoliflodacin
GyrB in silico mining in 27 151 global gonococcal genomes from 1928–2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibilityAuthor Name
Golparian
Date Published
October 2022
GIAPREZA®
Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shockAuthor Name
Garcia B, Su F, Dewachter L, Favory R, Khaldi A, Moiroux-Sahraoui A, Annoni F, Vasques-Nóvoa F, Rocha-Oliveira E, Roncon-Albuquerque R Jr, Hubesch G, Njimi H, Vincent JL, Taccone FS, Creteur J, Herpain A
Date Published
September 2022
XERAVA®
The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysisAuthor Name
Meng R, Guan X, Sun L, Fei Z, Li Y, Luo M, Ma A, Li H.
Date Published
September 2022
GIAPREZA®
A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgeryAuthor Name
Coulson TG, Miles LF, Serpa Neto A, Pilcher D, Weinberg L, Landoni G, Zarbock A, Bellomo R
Date Published
September 2022
XACDURO®
In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021Author Name
Karlowsky JA, Hackel MA, McLeod SM, Miller AA
Date Published
August 2022
GIAPREZA®
Angiotensin II enhances bacterial clearance via myeloid signaling in a murine sepsis modelAuthor Name
Leisman DE, Privratsky JR, Lehman JR, Abraham MN, Yaipan OY, Brewer MR, Nedeljkovic-Kurepa A, Capone CC, Fernandes TD, Griffiths R, Stein WJ, Goldberg MB, Crowley SD, Bellomo R, Deutschman CS, Taylor MD
Date Published
August 2022
GIAPREZA®
Effects of angiotensin II in the management of perioperative hypotension in kidney transplant recipientsAuthor Name
Andrews L, Benken J, Benedetti E, Nishioka H, Pierce D, Dalton K, Han J, Shin B, Benken S
Date Published
July 2022
GIAPREZA®
The Association Between Angiotensin II and Renin Kinetics in Patients After Cardiac SurgeryAuthor Name
Meersch M, Weiss R, Massoth C, Küllmar M, Saadat-Gilani K, Busen M, Chawla L, Landoni G, Bellomo R, Gerss J, Zarbock A
Date Published
May 2022
GIAPREZA®
The Role of Angiotensin II in Poisoning-Induced Shock-a ReviewAuthor Name
Chen A, Wong A
Date Published
April 2022
Zoliflodacin
Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection ModelAuthor Name
Jacobsson
Date Published
April 2022
Zoliflodacin
Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy AdultsAuthor Name
Newman
Date Published
November 2021
GIAPREZA®
Why the renin-angiotensin-aldosterone system (RAAS) in critically ill patients can no longer be ignoredAuthor Name
Zarbock A, Chawla L, Bellomo R
Date Published
November 2021
GIAPREZA®
Serum renin and major adverse kidney events in critically ill patients: a multicenter prospective studyAuthor Name
Flannery AH, Ortiz-Soriano V, Li X, Gianella FG, Toto RD, Moe OW, Devarajan P, Goldstein SL, Neyra JA
Date Published
August 2021
XACDURO®
Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With SulbactamAuthor Name
Shapiro AB, Moussa SH, McLeod SM, Durand-Réville T, Miller AA
Date Published
July 2021
Zoliflodacin
Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection ModelAuthor Name
Jacobsson
Date Published
May 2021
XACDURO®
A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjectsAuthor Name
O'Donnell J, Maloney K, Steidler M, Morrison R, Isaacs R
Date Published
May 2021
GIAPREZA®
Evaluating the evidence for angiotensin II for the treatment of vasoplegia in critically ill cardiothoracic surgery patientsAuthor Name
Chow JH, Wittwer ED, Wieruszewski PM, Khanna AK
Date Published
March 2021
Zoliflodacin
Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Neisseria gonorrhoeae Clinical Isolates in Nanjing, China, 2014 to 2018Author Name
Le
Date Published
February 2021
Zoliflodacin
High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018Author Name
Unemo
Date Published
February 2021
GIAPREZA®
A Multicenter Observational Cohort Study of Angiotensin II in ShockAuthor Name
Smith SE, Newsome AS, Guo Y, Hecht J, McCurdy MT, Mazzeffi MA, Chow JH, Kethireddy S
Date Published
November 2020
XERAVA®
Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical TrialsAuthor Name
Asempa TE, Izmailyan S, Lawrence K, Nicolau DP
Date Published
November 2020
XERAVA®
In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant EnterobacteriaceaeAuthor Name
Clark JA, Kulengowski B, Burgess DS
Date Published
September 2020
GIAPREZA®
Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing UseAuthor Name
Wieruszewski PM, Wittwer ED, Kashani KB, Brown DR, Butler SO, Clark AM, Cooper CJ, Davison DL, Gajic O, Gunnerson KJ, Tendler R, Mara KC, Barreto EF
Date Published
August 2020
GIAPREZA®
Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injuryAuthor Name
Leisman DE, Fernandes TD, Bijol V, Abraham MN, Lehman JR, Taylor MD, Capone C, Yaipan O, Bellomo R, Deutschman CS
Date Published
August 2020
GIAPREZA®
Angiotensin II for Critically Ill Patients With Shock After Heart TransplantAuthor Name
Cutler NS, Rasmussen BM, Bredeck JF, Lata AL, Khanna AK
Date Published
August 2020
XERAVA®
Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018Author Name
Lutgring JD, Balbuena R, Reese N, Gilbert SE, Ansari U, Bhatnagar A, Boyd S, Campbell D, Cochran J, Haynie J, Ilutsik J, Longo C, Swint S, Rasheed JK, Brown AC, Karlsson M
Date Published
August 2020
Zoliflodacin
Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea—challenges and opportunitiesAuthor Name
Theuretzbacher
Date Published
August 2020
GIAPREZA®
Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) StudyAuthor Name
Klijian A, Khanna AK, Reddy VS, Friedman B, Ortoleva J, Evans AS, Panwar R, Kroll S, Greenfeld CR, Chatterjee S
Date Published
August 2020
GIAPREZA®
Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory ShockAuthor Name
Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, Hästbacka J, Khanna AK, Albertson TE, Tumlin J, Storey K, Handisides D, Tidmarsh GF, Chawla LS, Ostermann M
Date Published
July 2020
GIAPREZA®
Use of Angiotensin II in Severe Vasoplegia After Left Pneumonectomy Requiring Cardiopulmonary Bypass: A Renin Response AnalysisAuthor Name
Trethowan B, Michaud CJ, Fifer S
Date Published
July 2020
XACDURO®
Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy SubjectsAuthor Name
Lickliter JD, Lawrence K, O'Donnell J, Isaacs R
Date Published
June 2020
XACDURO®
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumanniiAuthor Name
Seifert H, Müller C, Stefanik D, Higgins PG, Miller A, Kresken M
Date Published
June 2020
Zoliflodacin
Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant IsolatesAuthor Name
Bradford
Date Published
April 2020
XACDURO®
In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in ChinaAuthor Name
Yang Q, Xu Y, Jia P, Zhu Y, Zhang J, Zhang G, Deng J, Hackel M, Bradford PA, Reinhart H
Date Published
April 2020
GIAPREZA®
COVID-19 and the RAAS—a potential role for angiotensin II?Author Name
Busse LW, Chow JH, McCurdy MT, Khanna AK
Date Published
April 2020
XACDURO®
In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017Author Name
McLeod SM, Moussa SH, Hackel MA, Miller AA
Date Published
March 2020
GIAPREZA®
Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysisAuthor Name
Busse LW, Nicholson G, Nordyke RJ, Lee CH, Zeng F, Albertson TE
Date Published
March 2020
XACDURO®
Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute PyelonephritisAuthor Name
Sagan O, Yakubsevitch R, Yanev K, Fomkin R, Stone E, Hines D, O'Donnell J, Miller A, Isaacs R, Srinivasan S
Date Published
February 2020
GIAPREZA®
Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shockAuthor Name
Bellomo R, Wunderink RG, Szerlip H, English SW, Busse LW, Deane AM, Khanna AK, McCurdy MT, Ostermann M, Young PJ, Handisides DR, Chawla LS, Tidmarsh GF, Albertson TE
Date Published
February 2020
Zoliflodacin
High In Vitro Susceptibility to the First-in-Class Spiropyrimidinetrione Zoliflodacin among Consecutive Clinical Neisseria gonorrhoeae Isolates from Thailand and South AfricaAuthor Name
Jacobsson
Date Published
November 2019
XERAVA®
Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistanceAuthor Name
Solomkin JS, Sway A, Lawrence K, Olesky M, Izmailyan S, Tsai L
Date Published
October 2019
XERAVA®
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site AdministrationAuthor Name
Avery LM, Chen IH, Reyes S, Nicolau DP, Kuti JL
Date Published
October 2019
XERAVA®
Clinical Pharmacokinetics and Pharmacodynamics of EravacyclineAuthor Name
McCarthy MW
Date Published
September 2019
Zoliflodacin
Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor ZoliflodacinAuthor Name
Miller
Date Published
August 2019
XACDURO®
Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control SubjectsAuthor Name
O'Donnell J, Preston RA, Mamikonyan G, Stone E, Isaacs R
Date Published
August 2019
XERAVA®
Activity of cefiderocol (CFDC), ceftazidime-avibactam (CZA), and eravacycline (ERV) against carbapenem-resistant (CR) E. coli isolates from the US: Clonal Background, Resistance Genes, and Co-ResistanceAuthor Name
Johnston BD, Thuras P, Porter SB, Anacker M, VonBank B, Snippes Vagnone P, Witwer M, Castanheira M, Johnson JR.
Date Published
June 2019
GIAPREZA®
Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trialAuthor Name
Ham KR, Boldt DW, McCurdy MT, Busse LW, Favory R, Gong MN, Khanna AK, Chock SN, Zeng F, Chawla LS, Tidmarsh GF, Ostermann M
Date Published
June 2019
XACDURO®
Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic AgentAuthor Name
Barnes MD, Kumar V, Bethel CR, Moussa SH, O'Donnell J, Rutter JD, Good CE, Hujer KM, Hujer AM, Marshall SH, Kreiswirth BN, Richter SS, Rather PN, Jacobs MR, Papp-Wallace KM, van den Akker F, Bonomo RA
Date Published
March 2019
XERAVA®
Eravacycline: A Review in Complicated Intra-Abdominal InfectionsAuthor Name
Scott LJ
Date Published
February 2019
Zoliflodacin
Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy VolunteersAuthor Name
O’Donnell
Date Published
December 2018
XERAVA®
IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal InfectionsAuthor Name
Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A, Evans D, Tsai L
Date Published
December 2018
Zoliflodacin
Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital GonorrheaAuthor Name
Taylor
Date Published
November 2018
XACDURO®
Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult SubjectsAuthor Name
Rodvold KA, Gotfried MH, Isaacs RD, O'Donnell JP, Stone E
Date Published
October 2018
XERAVA®
Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of EravacyclineAuthor Name
Newman JV, Zhou J, Izmailyan S, Tsai L.
Date Published
August 2018
XERAVA®
In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacyclineAuthor Name
Zhang Y, Lin X, Bush K
Date Published
June 2018
GIAPREZA®
Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin IIAuthor Name
Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, Kashani K, Szerlip HM, Prowle JR, Bihorac A, Finkel KW, Zarbock A, Forni LG, Lynch SJ, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Bellomo R
Date Published
June 2018
XERAVA®
Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysisAuthor Name
Thabit AK, Monogue ML, Newman JV, Nicolau DP.
Date Published
May 2018
Zoliflodacin
In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strainsAuthor Name
Damião Gouveia
Date Published
February 2018
XACDURO®
Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumanniiAuthor Name
McLeod SM, Shapiro AB, Moussa SH, Johnstone M, McLaughlin RE, de Jonge BLM, Miller AA
Date Published
January 2018
XACDURO®
Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant PorinAuthor Name
Iyer R, Moussa SH, Durand-Réville TF, Tommasi R, Miller AA
Date Published
December 2017
XACDURO®
Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by SulbactamAuthor Name
Shapiro AB
Date Published
November 2017
XERAVA®
In Vitro Activity of Eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides speciesAuthor Name
Goldstein EJC, Citron DM, Tyrrell KL.
Date Published
October 2017
XACDURO®
Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514Author Name
Shapiro AB, Gao N, Jahić H, Carter NM, Chen A, Miller AA
Date Published
August 2017
GIAPREZA®
Angiotensin II for the Treatment of Vasodilatory ShockAuthor Name
Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hästbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM
Date Published
August 2017
GIAPREZA®
Clinical Experience With IV Angiotensin II Administration: A Systematic Review of SafetyAuthor Name
Busse LW, Wang XS, Chalikonda DM, Finkel KW, Khanna AK, Szerlip HM, Yoo D, Dana SL, Chawla LS
Date Published
August 2017
XERAVA®
In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection ModelAuthor Name
Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR
Date Published
July 2017
XACDURO®
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumanniiAuthor Name
Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, Lahiri S, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Velez-Vega C, Olivier NB, McLaughlin R, Gao N, Thresher J, Palmer T, Andrews B, Giacobbe RA, Newman JV, Ehmann DE, de Jonge B, O'Donnell J, Mueller JP, Tommasi RA, Miller AA
Date Published
June 2017
XERAVA®
Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical TrialAuthor Name
Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, Sutcliffe JA, Horn P
Date Published
March 2017
XERAVA®
A Divergent Route to EravacyclineAuthor Name
Zhang WY, Che Q, Crawford S, Ronn M, Dunwoody N.
Date Published
December 2016
Zoliflodacin
In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrioneAuthor Name
Papp
Date Published
July 2016
Zoliflodacin
Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodentsAuthor Name
Guo
Date Published
April 2016
Zoliflodacin
Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914Author Name
Giacobbe
Date Published
March 2016
Zoliflodacin
Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914)Author Name
Hong Su
Date Published
December 2015
Zoliflodacin
Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeaeAuthor Name
Foerster
Date Published
December 2015
Zoliflodacin
In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative PathogensAuthor Name
Biedenbach
Date Published
September 2015
Zoliflodacin
Update on Treatment Options for Gonococcal InfectionsAuthor Name
Lancaster
Date Published
September 2015
Zoliflodacin
High In Vitro Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (AZD0914) among 873 Contemporary Clinical Neisseria gonorrhoeae Isolates from 21 European Countries from 2012 to 2014Author Name
Unemo
Date Published
August 2015
Zoliflodacin
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesAuthor Name
Basarab
Date Published
July 2015
Zoliflodacin
Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)Author Name
Basarab
Date Published
July 2015
Zoliflodacin
In Vitro Antibacterial Activity of AZD0914 against Human Mycoplasmas and UreaplasmasAuthor Name
Waites
Date Published
May 2015
Zoliflodacin
Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria gonorrhoeaeAuthor Name
Alm
Date Published
February 2015
XACDURO®
Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumanniiAuthor Name
Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA
Date Published
February 2015
Zoliflodacin
In Vitro Antibacterial Activity of AZD0914, a New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-Positive, Fastidious Gram-Negative, and Atypical BacteriaAuthor Name
Huband
Date Published
December 2014
Zoliflodacin
Synthesis of a Tetrahydronaphthyridine Spiropyrimidinetrione DNA Gyrase Inhibiting Antibacterial Agent – Differential Substitution at all Five Carbon Atoms of Pyridine.Author Name
Basarab
Date Published
December 2014
Zoliflodacin
In Vitro Activity of AZD0914, a Novel DNA Gyrase Inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniaeAuthor Name
Kohlhoff
Date Published
November 2014
GIAPREZA®
Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot studyAuthor Name
Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, Seneff MG
Date Published
October 2014
Zoliflodacin
Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo CharacterizationAuthor Name
Basarab
Date Published
October 2014
Zoliflodacin
High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of GonorrheaAuthor Name
Jacobsson
Date Published
August 2014
XERAVA®
Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal InfectionsAuthor Name
Solomkin JS, Gardovskis J, Lawrence K, Montravers P, Sway A, Evans D, Tsai L
Date Published
April 2014
XERAVA®
Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical DevelopmentAuthor Name
Ronn M, Zhu Z, Hogan P, Zhang W, Niu J, Katz CE, Dunwoody N, Gilicky O, Deng Y, Hunt DK, He M, Chen C, Sun C, Clark RB, Xiao X
Date Published
April 2013
XERAVA®
Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline AntibioticAuthor Name
Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, Wilson DN, Sutcliffe JA.
Date Published
February 2012
XERAVA®
Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad Spectrum Antibacterial AgentAuthor Name
Xiao XY, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, Grossman TH, O'Brien WJ, Plamondon L, Rönn M, Sun C, Zhang WY, Sutcliffe JA
Date Published
December 2011
Zoliflodacin
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914Author Name
Kern
Date Published
October 2024
Zoliflodacin
Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection—Clinical Trial Group Programmatic MeetingAuthor Name
Cristillo
Date Published
October 2024
Request Medical Information
To speak to a Innoviva Specialty Therapeutics Information Professional, please visit our Contact page.
Report a Product Complaint
To report a complaint about an Innoviva Specialty Therapeutic product, please visit our Product Complaint page.
Report an Adverse Event
To report an adverse event with an Innoviva Specialty Therapeutic product, please visit our Adverse Event page.